Filing Details

Accession Number:
0001209191-23-042305
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-07-14 18:52:12
Reporting Period:
2023-07-12
Accepted Time:
2023-07-14 18:52:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX Biological Products, (No Disgnostic Substances) (2836) 464099738
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1786484 Terry-Ann Burrell C/O Recursion Pharmaceuticals
41 S. Rio Grande Street
Salt Lake City UT 84101
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Disposition 2023-07-12 24,302 $11.25 147,545 No 4 S Direct
Class A Common Stock Disposition 2023-07-12 78,071 $12.15 69,474 No 4 S Direct
Class A Common Stock Disposition 2023-07-12 3,195 $13.18 66,279 No 4 S Direct
Class A Common Stock Disposition 2023-07-12 3,157 $14.08 63,122 No 4 S Direct
Class A Common Stock Disposition 2023-07-13 8,275 $12.59 54,847 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.
  2. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.60 to $11.59 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
  3. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.60 to $12.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
  4. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.76 to $13.72 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
  5. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.81 to $14.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
  6. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.105 to $12.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.